Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevos antibióticos multipotentes para cepas multirresistentes

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20160810001
Publicado:
15/08/2016
Caducidad:
15/08/2017
Resumen:
Científicos de una universidad alemana han diseñado nuevas defensinas quiméricas con alta actividad contra las cepas de E. coli y S. aureus. La universidad ha identificado y aislado péptidos antimicrobianos de una amplia variedad de organismos, incluyendo humanos, donde participan en la primera línea de defensa contra patógenos. Entre estos péptidos se encuentran las defensinas, una familia de péptidos antimicrobianos. La universidad busca una compañía farmacéutica para continuar con el desarrollo y comercializar un nuevo tratamiento, por ejemplo, para infecciones hospitalarias con patógenos resistentes a múltiples medicamentos. El objetivo es establecer acuerdos de investigación, comercialización con asistencia técnica para dirigir los ensayos o licencia.

Details

Tittle:
Multipotent new antibiotics, also for multiresistant strains
Summary:
Scientists at a German University have designed novel human chimeric defensins molecules with high activity against E. coli and S. aureus strains. A pharmaceutical company is sought for further development up to commercialisation of the novel treatment concept, e. g. for hospital infections with multidrug-resistant pathogens. Types of partnership considered are research cooperation agreement, commercial agreement with technical assistance to conduct trials or license agreement.
Description:
Multidrug-resistant organisms represent a growing challenge in medicine, e. g. in the case of hospital infections. Thus, there is a strong need for novel treatment concepts.

Scientists at a German University working in the field of biochemistry developed two chimeric peptides based on human beta-defensins showing a broad spectrum of antimicrobial activities against many human multidrug-resistant pathogens. These two designer peptides of human origin represent promising templates for a new class of antibiotics.

Antimicrobial peptides (AMPs) have been identified and isolated from a wide variety of organisms, including humans, where they mostly participate in the first line of defense against pathogens. Among them are the defensins, a family of small antimicrobial peptides.

Despite partial sequence identity and structural similarity, different classes of human beta-defensins (namely, HBD 3 and HBD2) show different antimicrobial efficiencies. The design and characterization of HBD2/HBD3 chimeric peptides by scientists at the German University revealed that distinct molecular regions are responsible for their divergent killing properties. Combining these different regions in one molecule resulted in chimeric beta defensins with superior characteristics.

Two of these chimeric peptides, C3 and C5, showed an enhanced activity compared to that of their parent molecules and therefore were tested further against a broad range of multidrug-resistant pathogens. They killed both E. coli and S. aureus with an even higher efficacy than the wild-type molecules. Moreover, one of these two chimeras maintained its high killing activities in the presence of physiologic salt concentrations. The high activity against these pathogens makes these molecules promising candidates for clinical studies, as well as promising templates for a new class of antibiotics.

The proof-of-principle in vitro is shown. The scientists are preparing in vivo tests. Strong patent protection exists.
Partners are now needed for further development, e. g. to design and conduct clinical trials, as well as for commercialisation of this novel class of antibiotics. Types of partnership considered are research cooperation agreement, commercial agreement with technical assistance or license agreement.
Advantages and Innovations:
· Improved biological activity compared to natural defensins
· Strong microbial activity against a broad range of human Gram-negative and Gram-positive pathogens
· Activity also against multiresistant strains (extended spectrum lactamase, vancomycin-resistant enterococci, and methicillin-resistant S. aureus)
· Killing efficiently at very low concentrations
· No hemolytic activity against fresh human erythroctes
· Strong patent position: absolute product protection, US granted, EP granted soon
· Patent claims: peptide sequence, treating a microbial infection, coating medical devices (catheter, instrument, implant, contact lens)
Stage of Development:
Under development/lab tested
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
· Strong patent position: absolute product protection, US granted, EP granted soon
· Patent claims: peptide sequence, treating a microbial infection, coating medical devices (catheter, instrument, implant, contact lens)

Partner sought

Type and Role of Partner Sought:
A pharmaceutical company is sought as licensee or as partner for further development (e. g. design and execution of clinical trials) up to commercialization of the novel treatment concept.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06002001 Bioquímica / biofísica
06002009 Diseño molecular
06002008 Microbiología
06001015 Productos farmacéuticos / medicamentos
06001018 Virus, virología / antibióticos / bacteriología